



Dkt. 43016-B/JPW/SHS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#228 9/10/99  
T. Gray

Applicants : Philip Livingston and Friedhelm Helling  
U.S. Serial No.: 08/477,097 Group Unit: 1645  
Filed : June 7, 1995 Examiner: A. Caputa  
For : GANGLIOSIDE-KLH CONJUGATE VACCINE PLUS QS-21

1185 Avenue of the Americas  
New York, New York 10036  
June 30, 1999

Assistant Commissioner for Patents  
Washington, D.C. 20231

SIR:

SUPPLEMENTAL AMENDMENT TO THE RESPONSE FILED MAY 17, 1999

This Amendment is submitted to supplement the response filed May 17, 1999. Applicants filed a Response to an April 15, 1999 Final Office Action and as a First submission pursuant to a Communication Requesting Withdrawal of Finality under 37 C.F.R. 1.129(a) of the an April 15, 1999 Final Office Action and Petition for a Five Month Extension of Time. With the five-month extension of time, a response to the April 15, 1999 Office Action was due May 15, 1999. However, since May 15, 1999 was a Saturday, the next succeeding day which is not a Saturday, Sunday or Federal holiday, i.e. Monday, May 17, 1999, was considered timely under 37 C.F.R. §1.7. Accordingly, the subject application is pending and this supplemental response is considered timely.

Please amend the application as follows:

In the claims

Please amend claims 53, 56-57, 64-65 under the provisions of 37 C.F.R. § 1.121(b) by deleting the bracketed material and inserting the underlined material. Please add new claim 77.

G<sup>1</sup> --53. (2X Amended) A composition comprising a GM2 or GD2 ganglioside conjugated through the ceramide portion of